Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/08/2019|
|Rapid review completed||03/09/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||09/09/2019|
|Pre-submission consultation with Applicant||02/12/2019|
|Initial submission received from Applicant||02/03/2020|
|Complete submission received from Applicant||06/03/2020|
|Preliminary review sent to Applicant||24/04/2020|
|NCPE assessment re-commenced||05/06/2020|
|Factual accuracy sent to Applicant||14/08/2020|
|NCPE assessment re-commenced||21/08/2020|
|NCPE assessment completed||18/09/2020|
|NCPE assessment outcome||The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2021.